Initial Approach to Pancytopenia

Immediate Assessment and Stabilization

The initial approach to pancytopenia requires immediate assessment of severity with complete blood count and peripheral blood smear, followed by bone marrow examination in most cases to identify the underlying etiology, while simultaneously initiating supportive care based on the degree of cytopenias 1
Assess for life-threatening complications first, such as signs of severe infection or active bleeding, requiring immediate intervention 1
Obtain a focused history, including drug exposures, recent infections, autoimmune symptoms, and family history of bone marrow disorders, as recommended by the Journal of Clinical Oncology 2, 3
Physical examination priorities include looking for pallor, petechiae/purpura, hepatosplenomegaly, lymphadenopathy, and signs of infection, as suggested by the Journal of Clinical Oncology and Praxis Medical Insights 2, 1

Complete blood count with differential and reticulocyte count is essential to confirm pancytopenia severity and assess bone marrow response, according to the Journal of Clinical Oncology and Praxis Medical Insights 2, 1, 4
Peripheral blood smear examination is critical to identify schistocytes, blasts, megaloblastic changes, or dysplastic features, as recommended by the Journal of Clinical Oncology and Praxis Medical Insights 2, 3
Basic metabolic panel and liver function tests, including LDH, haptoglobin, and bilirubin, should be performed to assess for hemolysis, as suggested by the Journal of Clinical Oncology 2
Coagulation studies, such as PT, PTT, and fibrinogen, should be done to rule out DIC, according to the Journal of Clinical Oncology 2
Infectious workup, including HIV, HCV, CMV serology, and blood cultures, should be performed if febrile, as recommended by the Journal of Clinical Oncology and Praxis Medical Insights 2, 3

For severe anemia, transfuse packed red blood cells to achieve a hemoglobin level of 7-8 g/dL, as suggested by the Journal of Clinical Oncology and Praxis Medical Insights 2, 1, 4
For severe neutropenia, implement strict infection control measures and consider prophylactic antibiotics, according to Praxis Medical Insights 1, 4
For severe thrombocytopenia, platelet transfusion is indicated if active bleeding or platelet count is less than 10,000/μL, as recommended by Praxis Medical Insights 1

Bone marrow examination, including both aspiration and biopsy, is essential for diagnosing myelodysplastic syndromes and identifying chromosomal abnormalities, as suggested by Praxis Medical Insights 3
Cytogenetic analysis is necessary for diagnosing myelodysplastic syndromes and guiding prognosis and treatment, according to Praxis Medical Insights 3

For megaloblastic anemia, administer folic acid and vitamin B12 replacement, as recommended by the Journal of Clinical Oncology 2
For aplastic anemia, consult hematology immediately for consideration of immunosuppressive therapy or hematopoietic stem cell transplantation, according to Praxis Medical Insights 1, 3, 4
For immune-related pancytopenia, including immune checkpoint inhibitor-related, hold the offending agent, consult hematology, and administer prednisone, as suggested by the Journal of Clinical Oncology and Praxis Medical Insights 2, 1

Do not delay bone marrow examination, as aspiration alone is frequently inadequate, according to Praxis Medical Insights 3
Do not miss megaloblastic anemia, as it is a rapidly reversible cause of pancytopenia, as recommended by the Journal of Clinical Oncology 2
Do not use purine analogs in patients with active infection, and consider less myelosuppressive options, according to Praxis Medical Insights 3
Do not overlook drug-induced causes, such as methotrexate, which can cause pancytopenia even with low-dose weekly therapy, as suggested by Praxis Medical Insights 3
Avoid tetracycline antibiotics, as they can worsen blood abnormalities, according to Praxis Medical Insights 4
Use azathioprine cautiously, as it can cause bone marrow suppression in pre-existing pancytopenia, as recommended by Praxis Medical Insights 4